Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 27Breast Neoplasms 23Neoplasm Metastasis 14Glioma 14Carcinoma, Non-Small-Cell Lung 14Lymphoma 12Lung Neoplasms 11Glioblastoma 11Neuroblastoma 10Lymphoma, Non-Hodgkin 9Carcinoma, Renal Cell 9Brain Neoplasms 9Medulloblastoma 8Ovarian Neoplasms 7Neoplasms 7Multiple Myeloma 7Ependymoma 7Carcinoma, Hepatocellular 7Wilms Tumor 6Thyroid Neoplasms 6Sarcoma 6Rectal Neoplasms 6Pancreatic Neoplasms 6Osteosarcoma 6Melanoma 6Fallopian Tube Neoplasms 6Central Nervous System Neoplasms 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5

Interventions

Paclitaxel 5Carboplatin 3Taxes 2Specimen Handling 2Nivolumab 2Biopsy 2rucaparib 1rebastinib 1pembrolizumab 1olaparib 1durvalumab 1cediranib 1capivasertib 1cabozantinib 1Magnetic Resonance Spectroscopy 1LY-2157299 1Immunoglobulin G 1Ifosfamide 1Fluid Therapy 1Disulfides 1DCC-2036 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinosarcoma × Magnetic Resonance Spectroscopy × Clear all
NCT03367741 2026-06-02

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
82 enrolled 11 charts
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡